INCORTA
8.6.2021 17:14:04 CEST | Business Wire | Press release
Incorta , the Direct Data Platform™, today announced a multi-year partnership with MDSap , a sub-holding of Midis Group, a global leader in redistributing and reselling, to expand its go-to-market in the Middle East, Turkey, and Eastern Europe and address the region’s growing need for modern analytics and business intelligence. The partnership will provide MDSap’s 400 global enterprise customers with a fast and scalable data analytics solution, bringing Incorta’s Direct Data Platform to key regions such as the Middle East, North Africa, Turkey and Eastern Europe.
The COVID-19 pandemic spurred a rapid increase in the need for advanced technology, and Incorta’s presence in the Middle East is expected to grow by more than 100% this year – a market valued at $11 billion in 2020 and expected to reach $28 billion by 2026. The partnership will help replace outdated, legacy solutions, bringing modern data analytics to new and existing customers at unprecedented speed and scale.
“We’re thrilled to partner with Incorta to bring their state-of-the-art data analytics solution to our enterprise customers,” said Tony Achkar, group managing director of MDSap. “As the Middle East, Turkey and Eastern Europe regions continue to experience rapid digitization, our customers need a modern solution to help them keep up with today’s pace of business. Incorta is allowing them to analyze their data at a level of speed and scale they’ve never seen before.”
As SAP’s gold partner, MDSap leverages SAP technology and other solution providers to help businesses run smoothly and efficiently. Making smart, data-informed decisions is a key part of operating a business, as MDSap customers require the ability to quickly analyze, ingest and then act on their data in order to gain crucial insights about their business. Incorta’s Direct Data Platform will enable users to analyze massive sets of data at lightning speed, allowing them to maximize the full value of their data.
“The Middle East presents exciting opportunities for digital transformation and growth, especially in the data analytics market,” said Incorta CEO Scott Jones. “We are proud to be partnering with MDSap to help more companies in the region innovate and thrive with tools for making the most of their business data.”
The Incorta and MDSap integration is available now.
For more information, visit https://www.incorta.com/partners/mdsap .
About Incorta
Incorta is the only unified data analytics platform powered by Direct Data Mapping™. Purpose-built to help companies stay ahead of the accelerating rate, volume, and complexity of modern enterprise data, the platform delivers unmatched speed and visibility. Incorta is built with open standards and integrates with cloud-friendly tools and platforms, making it easy to consolidate data in the cloud and extract meaningful insights. By making any data source continuously available for analytics, the platform helps business leaders, business teams, and data scientists make more accurate, timely and transparent decisions with faster access to richer data sets. Backed by GV (formerly Google Ventures), Kleiner Perkins, M12 (formerly Microsoft Ventures), Telstra Ventures and Sorenson Capital, Incorta powers analytics for some of the most valuable brands in the world, including Broadcom, Credit Suisse and Shutterfly. To learn more and try it for yourself, visit www.incorta.com .
About MDSap
MDSap, a gold partner of SAP and expert in SAP’s banking solutions, has over 25 years of in-depth experiences helping customers manage, integrate, analyse and mobilize business mission critical data across the enterprise. The company has an exceptional track record providing turnkey IT solutions across the Middle East, Turkey & Central Eastern Europe to over 400 enterprise customers and government entities. MDSap is part of the Midis Group and is a member of EPM International and currently operates 10 offices across the Middle East, Turkey and Central Eastern Europe.
For more information, visit https://www.mdsaptech.com/en/ .
About Midis Group
With more than 5,000 professionals, representing the top 100 global IT vendors, and a solid 50-year track record of performance and reliability, the Midis Group is an international organization of over 170 companies across Europe, the Middle East & Africa. The group is known for its advanced offering of managed IT services and consultancy, system integration, cloud and data center capabilities and infrastructure, software and hardware solutions, as well as technology distribution and retail. It was named in 2006 as one of the World Economic Forum’s initial 100 Global Growth Companies. The group focuses on providing the best in services, with integrity, to vendors, partners, and customers across the destinations it serves. For more information, visit: www.midisgroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005870/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom